1. Show article details.

    Horizon Therapeutics plc Among Top Companies for Overall Corporate Reputation in 2021 Global PatientView Survey of Patient Groups Worldwide

    Business Wire – 8:01 AM ET 04/27/2022

    Horizon Ranked in Top Five for Patient Centricity, Patient-Group Relations and High Integrity Horizon Therapeutics plc (HZNP) today announced that it ranked fifth in overall corporate reputation among patient groups that have worked directly with the company and seventh among patient groups who were familiar with the company.

  2. Show article details.

    Horizon Therapeutics and Massachusetts Institute of Technology (MIT) Solve Announce Second Annual Horizon Prize to Inspire Solutions that Improve the Quality of Life for the Global Rare Disease Community

    Business Wire – 9:00 AM ET 04/19/2022

    Horizon Therapeutics plc (HZNP) today announced the kickoff of the second annual global innovation challenge, The Horizon Prize powered by MIT Solve. The Horizon Prize poses a unique question to encourage entrepreneurs and innovators worldwide to think creatively to solve a problem faced by the more than 400 million people globally living with a rare disease.

  3. Show article details.

    Horizon Therapeutics plc to Release First-Quarter 2022 Financial Results and Host Webcast on May 4, 2022

    Business Wire – 8:00 AM ET 04/14/2022

    Horizon Therapeutics plc (HZNP) announced today that it will release its first-quarter 2022 financial results on Wednesday, May 4, 2022. The live webcast and a replay may be accessed at http://ir.horizontherapeutics.com. Please connect to the Company’s website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast.

  4. Show article details.

    Eton Pharmaceuticals Names James Gruber Finance Chief

    Benzinga – 4:40 PM ET 04/11/2022

    Eton Pharmaceuticals Names James Gruber Finance Chief

  5. Show article details.

    Horizon Therapeutics plc Named One of the Fortune 100 Best Companies to Work For®

    Business Wire – 9:20 AM ET 04/11/2022

    Horizon Therapeutics plc (HZNP) today announced that it has been named one of Fortune’s 100 Best Companies to Work For® for the second consecutive year. “We are proud to be named to the Fortune 100 Best Companies to Work For list for the second time,” said Tim Walbert, chairman, president and chief executive officer, Horizon.

  6. Show article details.

    Executives Sell More Than $262M Of 5 Stocks

    Benzinga – 1:06 PM ET 04/04/2022

    Although gold futures traded higher on Monday, there were a few notable insider trades. When insiders sell shares, it indicates their concern in the company's prospects or that they view the stock as being overpriced. Below is a look at a few recent notable insider sales. Also check this: Insiders Buying These 4 Penny Stocks Have a look at our premarket coverage here .

  7. Show article details.

    Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2022

    Benzinga – 11:16 AM ET 03/15/2022

    For Turquoise Hill Resources Ltd, BMO Capital upgraded the previous rating of Underperform to Market Perform. According to BMO Capital, the prior rating for Turquoise Hill Resources Ltd was changed from Underperform to Market Perform. According to DA Davidson, the prior rating for Washington Federal Inc was changed from Neutral to Buy.


Today's and Upcoming Events

  • Aug

    HZNP to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May

    HZNP announced Q1 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.

Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

See the Latest Features
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.